Get started

BIO

$MLNT Breaks Out Ahead of Upcoming 9 Presentations at ECCMIDVery undervalued stock. 52 Week High was $46.00 52 Week Low was $3.22 Revenue for the 4th quarter of 2018 was $35.5 million, an 739% increase year over year. Total revenue for the year is $96.4 million. Could do 2x-3x from this level. Key data presentations at ECCMID 2019 include: Integrated Symposium Presentations •“Update on acute bacterial skin and skin structure infection: current challenges and new therapeutic agents,” chaired by Javier Garau, M.D., Ph.D. (Saturday, April 13, 1:30 - 3:30 p.m., Hall D) •“Light and shadows in the management of serious MDR G-negative infections,” chaired by Matteo Bassetti, M.D. (Monday, April 15, 4:00 p.m. – 6:00 p.m., Hall F) Oral Presentation •Abstract No. 3623 (Sunday, April 14, 11:00 a.m. - 12:00 p.m. CET, Exhibit Hall L): Development and Validation of a Risk Stratification Score for a Mixed Gram-Negative and Gram-Positive Infections among Patients Hospitalized with Skin and Skin Structure Infections in the U.S., Y. Tabek, BD. Poster Presentations Meropenem/vaborbactam (VABOMERE®) •Abstract No. 8308 (Saturday, April 13, 3:30 - 4:30 p.m. CET, Paper Poster Area): Activity of meropenem-vaborbactam and single-agent comparators against KPC-producing Enterobacterales isolates from European countries (2016-2018) stratified by infection type, M. Castanheira, JMI Laboratories •Abstract No. 2825 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): Multicenter Evaluation of Meropenem/Vaborbactam MIC Results for Enterobacteriaceae and Pseudomonas aeruginosa Using MicroScan Dried Gram-Negative MIC Panels, A. Harrington, Loyola University •Abstract No. 4780 (Monday, April 15, 12:30 - 1:30 p.m. CET, Paper Poster Area): ETEST meropenem/vaborbactam for antimicrobial susceptibility testing of Enterobacterales and Pseudomonas aeruginosa: performance results from a multi-centre study, C. Anglade, bioMérieux, Inc. •Abstract No. 7426 (Tuesday, April 16, 12:30 - 1:30 p.m. CET, Paper Poster Area): An FDA-approved study for an AST disc 510(k) submission: comparison of an oxoid AST disc to a predicate AST disc for meropenem-vaborbactam, N. Hunter, Thermo Fisher Scientific Delafloxacin (BAXDELA®) •Abstract No. 6363 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Delafloxacin tentative ECOFF values for common Gram-positive and Gram-negative bacteria, G. Menchinelli, Università Cattolica del Sacro Cuore Oritavancin (ORBACTIV®) •Abstract No. 4151 (Monday, April 15, 1:30 - 2:30 p.m. CET, Paper Poster Area): Oritavancin Activity against Staphylococcus aureus Clinical Isolates Causing Serious Infections in Hospitalized Patients in Europe (2017-2018), C. Carvalhaes, JMI Laboratories marketwirenews.com
MLong
by StockGuild
$CELZ Continues North with Accelerating Accumulation$CELZ is currently on a clear and clean breakout in anticipation of the May 18th- 21st Presentation at the American Urological Association Convention in San Francisco. An 8K was released recently showing that shares were issued at .10 and as high as .30 levels The following link shows that the CEO has been buying on the way up as well: backend.otcmarkets.com Look who covered $OWCP (Which ran from .003 to >> $3.05) and has been covering CELZ since Feb 18, 2018 (PPS @ .0094 at that time) CORRELATION? ;-) ----> t.co Also forgot to mention the debt is almost completely eliminated from the books :-)
CLong
by StockGuild
4
$CELZ Begins Breaking out on High buy Volume on News Release$CELZ broke above prior high on the last leg after a release of 8-Ks showing the clearing up of the rest of the company's debt and notes. Item 1.01 Entry into a Material Definitive Agreement Effective April 11, 2018, Creative Medical Technology Holdings, Inc. (the “ Company ”) amended promissory notes issued by it and by its operating subsidiary, Creative Medical Technology, Inc., to Creative Medical Health, Inc. (“ CMH ”), the parent of the Company, to permit the conversion of the notes into restricted shares of common stock of the Company. The 8% promissory notes were originally issued February 2, 2016, in the principal amount of $50,000, on May 1, 2016, in the principal amount of $50,000, and on May 18, 2016, in the principal amount of $25,000. The conversion formula on the principal and accrued interest on the amended notes is 120% of the 30-day volume weighted average price (VWAP) for the Company’s common stock traded March 1, 2018 through March 30, 2018. Immediately upon amendment of the notes, CMH converted the total outstanding principal and interest of the notes, which was $136,003. The VWAP for the 30-day period ended March 30, 2018, was $0.0138 and the number of shares issued to CMH for the conversion was 9,855,290 restricted common shares. Item 3.02 Unregistered Sales of Equity Securities In connection with the conversion of the notes disclosed under Item 1.01 above, the Company issued 9,855,290 shares of common stock to CMH without registration. The issuance of these securities was made pursuant to Rule 506(b) of Regulation D promulgated by the SEC under the Securities Act as a transaction not involving any public offering. No selling commissions or other remuneration were paid in connection with the issuance of these shares. Item 8.01 Other Events On April 12, 2018, the Company issued a press release announcing the amendment to the CMH notes and the conversion of the notes into common stock of the Company. From April 12, 2018 through April 19, 2018, we issued an aggregate of 114,017,952 shares upon the conversions of outstanding notes and 15,009,325 shares upon the cashless exercise of outstanding warrants. These conversions were made pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933. As a result of these issuances, we have outstanding 609,062,989 shares of common stock as of April 19, 2018.
CLong
by StockGuild
$IDXG On a Clear Breakout with Potential News Down Pipeline$IDXG Latest Insider Purchases, Institutional Ownerships and News: 2016-02-03 Glorikian Harry Director Acquired 127,696 2016-02-03 KEEGAN JOSEPH D Director Acquired 127,696 2016-02-03 STOVER JACK E Interim President and CEO Director Acquired 294,756 2016-02-03 SULLIVAN STEPHEN J Director Acquired 295,656 2017-06-23 SC 13G ARMISTICE CAPITAL, LLC Acquired 965,784 John P. Dugan (Founder): 4,869,878 common shares Other Insiders Approximately: 2,672,149 shares collectively Total Insiders: 7,542,027 shares Institutional Ownership: 30.6% 5.5 mil shares (Increased to 6.5 mil as of June 23rd) Largest Institutional Holder: Heartland Advisors: 2,994,313 Recent News Headlines: 2017-06-28 Interpace Diagnostics Announces National Contract With Aetna 2017-06-26 Interpace Diagnostics Announces Coverage Of Thyroid Test By Premera Blue Cross 2017-06-16 Interpace Diagnostics Announces Pricing Of $13.7 Million Underwritten Public Offering Of Common Stock And Common Warrants 2017-06-06 Interpace Diagnostics Announces Agreement With Einstein Medical Center Of Philadelphia 2017-05-25 Interpace Diagnostics Announces Launch Of Enhancement To Thyroid Testing Services 2017-05-16 Interpace Diagnostics Group's (IDXG) CEO Jack Stover on Q1 2017 Results - Earnings Call Transcript 2017-05-15 Interpace Diagnostics To Host Conference Call And Webcast To Discuss First Quarter 2017 Financial Results On Monday May 15, 2017 2017-05-10 Interpace Diagnostics Presents New Data on PancraGEN® at DDW 2017-04-20 Interpace Diagnostics Eliminates Long Term Secured Debt 2017-04-18 Interpace Diagnostics Announces Coverage Of ThyraMIR With UnitedHealthcare 2017-04-13 Interpace Diagnostics Announces Receipt of Letter From Nasdaq Confirming Compliance With Minimum Stockholders' Equity Requirement 2017-04-04 A Look at Interpace Diagnostics Financials, Drug Pipeline and Market Opportunity 2017-04-03 Interpace Diagnostics Announces European Patent Approval For Underlying Technology Of Its Thyramir Microrna Classifier
ILong
by StockGuild
$DCTH Mid Term Goals could put this over $1+ In Weeks - Repost -Reposting as it didn't post properly the first time $DCTH Highlights for the first quarter of 2017 and the recent weeks include: First quarter 2017 revenue of $0.74 million, an increase of 100% compared with revenue of $0.37 million in prior year quarter. CHEMOSAT treatment milestone set by SPIRE Southampton Hospital in the U.K. with more than 100 CHEMOSAT treatments performed, including eight treatments on a single patient. Announced a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the design of a pivotal trial of Melphalan/HDS to treat patients with intrahepatic cholangiocarcinoma (ICC). The American Journal of Clinical Oncology published a single-center retrospective review finding that the Company’s investigational percutaneous hepatic perfusion (PHP) with Melphalan/HDS offered promising results with a doubling of overall survival (OS), significantly longer progression-free survival (PFS) and hepatic progression-free survival (hPFS) compared with other targeted therapies. Favorable data from two institutions were presented at the Regional Cancer Therapies Symposium and showed strong tumor response and overall survival with the Company’s investigational PHP therapy in patients with ocular melanoma that metastasized to the liver. “During the first three months of 2017 we continued to advance our clinical development programs in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, while making steady progress with commercialization of CHEMOSAT in Europe,” said Jennifer K. Simpson, Ph.D., MSN, CRNP President and CEO of Delcath." “As we announced recently, we have concluded a new SPA agreement with the FDA for the initiation of a pivotal trial for the use of Melphalan/HDS in patients with ICC. This new trial will enroll approximately 295 ICC patients at about 40 clinical sites in the U.S. and Europe, with the primary endpoint of overall survival and with secondary and exploratory endpoints that include safety, progression-free survival, objective response rate and quality-of-life measures. The trial is designed to be cost-effective and conducted in a financially prudent manner, with modest investment in this fiscal year. In conjunction with the FOCUS Trial in ocular melanoma liver metastases, our clinical development programs now include two paths toward potential U.S. market approvals. “In Europe, we continue to make steady progress with the commercialization of CHEMOSAT. Our first quarter revenue of more than $0.7 million was double the prior year period’s sales, driven primarily by national reimbursement in Germany under the ZE system. With coverage under the ZE system now in place, we expect product sales growth from this market for the remainder of 2017." "Elsewhere in Europe, we continue to focus on building the clinical and pharmacoeconomic data to support reimbursement applications in other key markets. We expect that positive negotiations for coverage in Germany will support our efforts for payment levels in other markets such as the U.K. and the Netherlands. Securing reimbursement coverage in additional European markets remains critical to future revenue growth for CHEMOSAT,” concluded Dr. Simpson. As of March 31, 2017, Delcath had cash and cash equivalents of $6.4 million, compared with $4.4 million as of December 31, 2016. During the first quarter of 2017, the Company used $3.8 million of cash to fund operating activities. Delcath believes it has sufficient capital and access to committed capital to fund its operating activities through the end of 2017. Also check out this article, pretty good read: insiderfinancial.com
NASDAQ:DCTHLong
by StockGuild
ABBV BreakoutHuge breakout for ABBV closing the day above the double top formed from 2014/2015 highs between 70.70 and 71.60, both offering little resistance. RSI pushing into the high 80s shows good strong move up in my opinion, I won't be using RSI for short/sell/TP signal, rather buy more when it dips to over-sold territory on consolidation in the next few weeks... if that even happens. MACD indicator has room to continue upwards, watching MACD and EMA 20/50/200 crosses for a close trade signal. ABBV is still a strong buy for me. I went long after the previous longer term channel break near 70.10 last week, stop loss around 71.40 currently. GLHF!
NYSE:ABBVLong
by Dank-Traders
$CTRV 1st Conference Starts Tmrw Continues in the Right DrtnNothing entirely new to report. Closed above last major resistance and still continues to stair step in the right direction. I think it should be noted and I didn't mention it before but the corporations who took a stake in the company in the last two months: Maxim Group set a $4.00 price target on shares of ContraVir Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, April 11th. Noble Financial reaffirmed a “Buy” rating on shares of ContraVir Pharmaceuticals in a research report on Friday, April 21st. Teachers Advisors LLC boosted its position by 3.1% in the fourth quarter. Teachers Advisors LLC now owns 298,781 shares worth $1,820,000 Vanguard Group Inc. boosted its position in ContraVir Pharmaceuticals by 10.2% in the first quarter. Vanguard Group Inc. now owns 2,048,283 shares worth $3,626,000 after buying an additional 189,634 shares during the last quarter. Geode Capital Management LLC boosted its position by 2.0% in the first quarter. Geode Capital Management LLC now owns 353,777 shares worth $626,000 after buying an additional 7,057 shares during the last quarter. Morgan Stanley boosted its position in ContraVir Pharmaceuticals by 0.4% in the first quarter. Morgan Stanley now owns 278,798 shares worth $493,000 after buying an additional 1,119 shares during the last quarter. 5.49% of the stock is owned by institutional investors. Very nice averages stakes taken by numerous groups and this is a month or two before the conferences. Shows some agencies might have gotten a sneak peak at the upcoming info. $CTRV
CLong
by StockGuild
$CTRV Continues to trend upwards Amid Bio Conferences$CTRV announced today in addition to the 2017 Marcum MicroCap Conference 15-16 in New York, they will also be presenting at the San Diego Bio conference on June 19-22. Let's think about this hypothetically. If there was no news to present or bad news they wouldn't have more than one conference, I mean one conference would be more than enough to tell everything in either of those two cases also who wants to put themselves through the embarrassment of a second conference if there wasn't something good down the line. Only time will tell but it is looking good in the right direction. Also the techs are beyond bullish EMA / SMA crossover, PARSAR flip, resistance breaks support rebounds higher highs higher lows. All around very good. pbs.twimg.com
CLong
by StockGuild
$CTRV Runway Is Cleared for Take-Off$CTRV to present at the 2017 Marcum MicroCap Conference being held June 15-16. 2017, at the Grand Hyatt New York in New York City .60s on this stock has always been a massive support level since 2014. Go back far enough and you can see where the stock hits .60 and then moves back to multi-dollars. This CEO doesn't do R/S's he is an old school OG who knows how to move a stock and takes care of his shareholders while at the same time taking care of the company and business. Not to mention 3 drug candidates in clinical trials. Liking what I'm seeing here.
CLong
by StockGuild